Biannual Review of Exhaled Air and Trends in Health Evaluation in COPD
NCT07045948
Summary
This study aims to evaluate how airway inflammation, lung function, and symptoms change over time in people with chronic obstructive pulmonary disease (COPD). Airway inflammation will be assessed using a simple breath test (FeNO) and a small blood sample to measure eosinophils, a type of white blood cell. Participants will be followed for one year, with three study visits (at the start, 6 months, and 12 months). The goal is to understand how these markers evolve and whether they differ between people who experience a worsening of symptoms (called exacerbations) and those who remain stable. All tests except for a small extra blood draw are part of routine COPD care. Participation does not affect standard treatment.
Eligibility
Inclusion Criteria: * Adults aged ≥ 40 years * Diagnosed with COPD according to GOLD criteria * Attending routine follow-up visits every 6 months * Ability to provide informed consent Exclusion Criteria: * Recent respiratory tract infection or exacerbation (either moderate or se-vere) (\<4 weeks before inclusion) * Dominant asthmatic phenotype (ACO with asthma predominance) * Severe comorbidities interfering with participation or follow-up
Conditions1
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07045948